HLA-C and neoplasm: A recent report elucidated loss of heterozygosity (LOH) at the HLA alleles; in particular, loss of HLA-C*08:02 was observed in a resistant lesion treated with tumor-infiltrating lymphocytes composed of cytotoxic T cell clones targeting the KRAS G12D mutation [40].